Catalyst Pharmaceuticals Investor Relations Material

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. The company develops oral mid-kine receptor modulators for multiple indications for the treatment of neuromuscular weakness associated with amyotrophic lateral sclerosis. Catalyst Pharmaceuticals has a collaboration agreement with Memorial Sloan Kettering Cancer Center to develop drugs for muscle diseases associated with cancer or its treatment. It also develops a pipeline of compositions covering a range of applications including pain management, sleep disorders, and drug addiction.